Medical Device News Magazine

Coala Heart Monitor Late-breaking Trial Published in BMJ Advises Coala Life

Proves the Efficacy of Coala Heart Monitor As Part of Cryptogenic Stroke Management

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

October 14, 2020

Coala Heart Monitor: Results of a late-breaking trial on cryptogenic stroke (stroke of unknown cause) patients. In the TEASE-study, recently published in the British Medical Journal (BMJ Open, Aug 2020). The news was announced today by Coala Life, a Swedish innovator in remote cardiac and respiratory monitoring.

Coala Heart Monitor was used to evaluate 100 patients after cryptogenic stroke. Patients were recruited from two-stroke units in Sweden that underwent scheduled monitoring twice daily, and when symptoms occurred, for 28 days in everyday life.

The monitoring detected previously undiagnosed atrial fibrillation in 9% of the patients, at a mean of 19.7 days after stroke. Patient compliance to the Coala monitoring protocol exceeded 90%.

The prospective, real-world TEASE-study was led by Dr. Peter Magnusson, cardiologist at the Cardiology Clinic in Region Gavleborg, and with academic affiliations to the Karolinska Institute, Stockholm, and Uppsala University, Sweden.

“The study proves the efficacy of the Coala Heart Monitor in cryptogenic stroke patients with excellent patient compliance. We recommend a hand-held, non-invasive device like Coala Heart Monitor for long-term use as the main evaluation tool in the vast majority of cryptogenic stroke cases,” comments Dr. Peter Magnusson.

The TEASE-study detected previously undiagnosed atrial fibrillation in 9% of cryptogenic stroke patients, using the non-invasive Coala Heart Monitor, at mean 20 days post-stroke. In the CRYSTAL-AF study (NEJM, 2014) it took 6-months to detect AF in 8.9% of cryptogenic stroke patients by using an invasive insertable cardiac monitor.

The study is available with open access here.

Note: The COALA is ideal to prescribe to patients with palpitations and intermittent symptoms of possible arrhythmias that need a long-term monitoring solution.

Its unique dual-lead ECG solution captures accurate, clinically relevant cardiac data when symptoms occur. It’s the only smartphone-based solution with automatic AF detection based on advanced pattern recognition algorithms.

The real-time visibility to results ensures physicians can efficiently progress symptomatic patients along the treatment path.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”